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The purpose of this review is to give an overview of the identification and the characterization of Transient 
Receptor Potential Vanilloid 1 (TRPV1) in animal tissues. TRPV1 is a receptor belonging to the superfamily of 
Transient Receptor potential (TRP) and it was first identified in dorsal root ganglion in 1997. After, the scientific 
interest on this receptor increased, and nowadays it is possible to read a huge bibliography dealing with this 
receptor that is considered ubiquitarian. Actually, it was identified in the majority of animal and human tissues 
in physiological and pathological conditions. The involvement of TRPV1 receptor is considered as a key to 
understand aetiopathogenic mechanisms and to try to find a therapeutic treatment. In spite of the deep 
knowledge on TRPV1 molecular structure, more studies are required to better understand the cascade following 
its activation. For all the previous mentioned reasons, TRPV1 was investigated in species of interest of 
Veterinary Medicine and some of them are important animal models for human medicine, especially for 
oncology and analgesic therapeutic strategies. 
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Introduction 
Transient receptor potential vanilloid 1 (TRPV1) is a 
non-selective cation channel belonging to the superfamily of 
Transient Receptor Potential (TRP) (Fig.1). TRPV1 is 
composed by six transmembrane domains with a pore region 
between the fifth and the sixth segment (S5-S6). This 
structure (Fig.2) was confirmed by electron microscopy and 
forms a tetrameric structure with a central localized pore [1]. 
Both its C- and N- termini are located intracellularly and it 
was demonstrated that they are involved in the regulation of 
the channel activity [2]. The first demonstration of the 
presence of TRPV1 was performed by Caterina and 
colleagues [3]: this receptor was cloned in dorsal root 
ganglion (DRG) cells and the identification was performed 
using capsaicin, the active compound of hot chilli peppers. 
The capsaicin molecule has a vanilloid moiety and for this 
reason these receptors are interchangeably referred to as 
capsaicin or vanilloid receptors (VRs) [4]. 
As cited previously, TRPV1 is a non-selective cation 
channel with a high permeability to Ca2+ and that can exhibit 
macroscopic outward rectification [3]. TRPV1 activation 
induces the depolarization of sensory nerve endings, and 
consequently could evoke a sequence of potentials from the 
spinal cord to the brain [4]. Electrophysiological and genetic 
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studies demonstrated that TRPV1 is also activated by heat 
(>43°C) and that is involved in noxious thermal stimuli 
detection by primary sensory neurons [5,6]. Moreover, TRPV1 
is sensitized by chemical substances produced during 
inflammation, i.e. extracellular protons and lipid metabolites 
that directly interact with the channel and can potentiate the 
effects of capsaicin or heat [5,7,8] (Fig.3).  
TRPV1 of different species have been compared and 
evolutionary differences among vertebrates have been 
demonstrated by Saito and Shingai[9]. Especially in 
mammalians and birds, TRPV1 orthologues have been 
cloned, and their channel properties have been characterized 
in considerable details [10,11,12,13,14,15]. 
One of the most important differences exists with respect 
to sensitivity to capsaicin: rabbits and chickens are less 
sensitive to it than other vertebrates [11,14]. 
Saito and Shingai[9] identified four copies of mammalian 
thermo TRP homologs in chickens, nine in western clawed 
frogs, two in zebrafishes, and three in puffer fishes. The 
amino acid sequences of these TRPVs were aligned with 
those available in the databases and phylogenetic trees were 
reconstructed, using conserved portion containing ankyrin 
(ANK) repeat, transmembrane (TM), pore loop (PL), and 
TRP domains. According to the resulting findings, 
vertebrates’ TRPVs were divided into four major clusters: 
TRPV1/2, TRPV3, TRPV4, and TRPV5/6 [16]. Moreover, 
they can be distinguished in those that are responsive to 
capsaicin, i.e. human [10], rat [3], guinea pig [12], and mouse 
[13], and those that are not responsive for, i.e. rabbit [14]. The 
reason behind capsaicin sensitivity can be found in a single 
threonine residue at amino acid position 550 within the S3 to 
S4 region [14].  
All the similarities and the differences mentioned should 
be considered for comparative medicine researches because 
they could significantly influence experimental hypothesis 
and, consequently, the results. The following paragraphs deal 
with the mostly used experimental animal models and the 
most important similarities and differences between humans 
and animals will be highlighted.  
TRPV1 expression in animal species 
Mouse  
The identification of TRPV1 in mouse was performed 
cloning RNA isolated from mouse spinal cord, primers 
derived from TRPV1 orthologues, and partial murine 
sequences from GenBank (AC087118.4 7) [13]. Subsequently, 
TRPV receptors involvement in transducing thermal and 
inflammatory pain was investigated in mice lacking the 
TRPV1 gene: these animals demonstrated deficits in 
hyperalgesia induced by inflammation, but partly maintained 
sensitivity to noxious heat [4]. Other studies established that 
TRPV1 deficient mice do not display thermal 
hypersensitivity following tissue injury [17,18], substantiating 
the hypothesis that capsaicin receptor is a polymodal 
integrator of noxious chemical and physical stimuli in 
vivo[11,19] .  
It was demonstrated that direct phosphorylation by 
phosphokinase C (PKC) could activate TRPV1 and other cell 
surface receptors such as the purinergic receptor P2Y1, 
bradykinin BK2 receptor or the nerve growth factor (NGF) 
receptor TrkA[13]. The murine model was widely used in the 
past to study the modulation of TRPV1 activation via 
phorbol 12-myristate 13 acetate (PMA) inducing PKC 
phosphorylation. The study of Correll et al. [13] suggested that 
PMA-induced phosphorylation could decrease the heat 
threshold TRPV1 activation from 42°C to 32°C that means 
that TRPV1 could also be activated in a range of 
physiological temperatures, and that PKC-mediated 
phosphorylation could activate TRPV1. In contrast to this 
findings, other authors suggested that PMA-induced 
activation of PKC could only minimally activate TRPV1 
compared to capsaicin - evoked activation [20,21].  
The same study of Correll and colleagues [13] established 
that agonists like capsazepine, 5-iodio-resiniferatoxin 
(5-I-RTX) and BCTC against mice TRPV1 (mTRPV1) could 
have similar effects to that induce in rat TRPV1 (rTRPV1), 
while displaying significant differences compared to human 
TRPV1 (hTRPV1).  
Figure 1. Representation of Transient Receptor Potential 
superfamily.Transient Receptor Potential superfamily could be 
divided into different subfamiliyes: TRPV (vanilloid), TRPML 
(mucolipin), TRPC (canonical) TRPA (ankyrin), TRPM (melastatin) 
and TRPP (polycystin). 
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Rats 
TRPV1 was first identified in rat primary sensory neurons, 
and after it was recognized in different tissues and it was 
demonstrated is involvement in noxious thermal stimuli 
perception and propagation [3]. This result provided an 
important model system for the in vitro study of hyperalgesia 
and allowed to assume multiple implications of TRPV1 for 
comparative medicine researches. 
Human TRPV1 and animal TRPV1s were compared and it 
was possible to calculate a grade of homology between 
hTRPV1 and rat (rTRPV1, 85.7%), guinea pig (gpTRPV1, 
83.9%) and rabbit (oTRPV1, 87.8%) [13,14]. Nevertheless, 
responses to ligands could be extremely different considering 
the specific TRPV1: for instance, both human and guinea pig 
TRPV1s demonstrate little sensitivity to phorbol 
12-phenylacetate 13- acetate 20-homovanillate (PPAHV) 
comparing to rTRPV1[13]. 
TRPV1 was also identified in rat trigeminal ganglion 
during a study that investigated the role of TRPV1 in 
orthodontic pain responses: results revealed that 
TRPV1 expression is modulated by experimental tooth 
movement and is involved in tooth-movement pain [22].  
Rats were also used as experimental model for humans for 
bone pain. In the paper of Gui and colleagues [23], it was 
investigated the role of TRPV1 in bone pain following 
metastatic spread of breast cancer cells. TRPV1 positive 
neurons were more expressed in cancer-bearing rats and the 
substance P expression was not different, suggesting that 
TRPV1 responsive neurons were activated in the model [23]. 
Moreover, TRPV1 was identified in innervating femur in rat 
under physiological conditions and during osteoporosis it is 
possible to describe an increasing of TRPV1 expression [24].  
Other studies were focused on identification and 
characterization of TRPV1 in airway smooth muscle cells 
and tracheal mucosa in rats. Yamamoto et al. [25] showed 
thatthe intraepithelial nerve endings and dense subepithelial 
network of nerve fibres were immunoreactive for TRPV1 in 
the epithelial layer. They investigate also TRPV2 receptor 
that was observed mainly innervefibres of the tracheal 
submucosal layer and in several intrinsic ganglion cells in the 
peritracheal plexus[25]. Double immunostaining revealed that 
some TRPV1-immunoreactive nerve fibres were also 
immunoreactive for substance P or calcitonin gene-related 
peptide, but neither neuropeptide co-localized with TRPV2 
suggesting the possible involvement of TRPV1 in 
trachealnociception, and the different expression patterns 
ofTRPV1 and TRPV2 with neuropeptides may reflect 
different subpopulations of sensory neurons [25]. Zhao et al. [26] 
Figure 2. Molecular architecture of the vanilloid receptor. TRPVs are composed by six 
transmembrane segments (TM), a pore region between fifth and sixth segment, and cytoplasmatic N- 
and C-termini. These subunits constitute a tetramer around a central pore, responsible for the 
nonselective cation channel functions. The N-terminus can interact with cytosolic proteins, such as 
protein kinase A and C, Calcium/calmodulin-dependent protein kinase II. The cytosolic C-terminus 
domain carrying calmodulin (CaM) and phosphatydylinositol-4,5-bisphosphate (PIP2) binding sites. 
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demonstrated the expression and activity ofTRPV1 channel in 
proliferation of airway smooth muscle cells (ASMCs), one of 
the major contributors to airway remodelling and the basis of 
severe asthma. They highlighted that capsaicin inhibited 
apoptosis while capsazepine had the opposite effect. In human 
medicine, the study of McGarvey and colleagues [27] 
demonstrated that TRPV1 is overexpressed in patient with 
asthma and they hypothesised a therapeutic used of capsaicin 
to manage uncontrolled symptoms.   
Amphibians 
In amphibians, which are subject to thermal environmental 
variations (poikilothermal animals), the function of TRPV1 
still remains unknown [16]. An early study reported that 
capsaicin did not affect substance P release from the spinal 
cord, although it changed nociceptive responses to cutaneous 
stimuli in Rana esculenta[28]. It was suggested by Kuffler and 
colleagues [29] that molecules of the heat sensor in the frog 
lack vanilloid sensitivity, as capsaicin does not produce any 
membrane current in Rana pipiens heat-sensitive DRG 
neurons. They demonstrated that frog DRG neurons can 
produce membrane current similar to that in mammalian 
primary sensory neurons after noxious heat application. 
Anyway, this current, and consequently the activation of the 
receptor, is not influenced by vanilloid ligands, while acids 
can inactivate it[29]. Szolcsányi[30]confirmed that frogs are 
completely insensitive to capsaicin (contrary to rTRPV1, 
where capsaicin easily induces noxious thermal stimuli) and 
temperature does not evoke any membrane current[3; 29]. 
These results suggested that TRPV1 in frogs probably lacks 
the domain for binding vanilloids and that probably this 
species should not be used as animal experimental model. 
Rabbit  
Identification and characterization of rabbit TRPV1 was 
performed by Gavva and colleague [14]. To assess this 
identification, a rat-rabbit (r/o) TRPV1 chimera was create 
after restriction cloning, hybridization and stable 
transfection. Binding and functional assays were performed 
and finally also electrophysiology tests were made.  
This study demonstrate that cloned cDNA from a rabbit 
DRG appeared to be an orthologue of human TRPV1, 
primarily localized in sensory neurons, similar to both rat and 
human TRPV1. Binding assays using (3H) resiniferatoxin 
(RTX) were performed and the results shown that oTRPV1 
was relatively insensitive to vanilloid agonists, such as RTX, 
capsaicin, arvanil, and olvanil in comparison to rat and 
Figure 3.Multiple modes of TRPV1 activation. TRPV1 can be activated by a wide range of 
diverse chemical and physical stimuli. Chemical activation incorporates endogenous and 
exogenous agonists (many of them bind to the capsaicin side) and acidification (protonation of the 
receptor by H+ binding). Physical stimuli include heat (threshold of 42-43°C) and membrane 
potential (depolarization causes channel opening). The activation of TRPV1 is described as 
“polymodal” or “multimodal” because different stimuli can contribute t ion channel activity. 
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human TRPV1. Authors tried to explain this phenomenon 
(that is analogous to the observations published by Jordt and 
Julius in 2002 concerning gpTRPV1) saying that a 
substitution in TM3 and TM4 regions (specifically on 
Ser505-Thr550) can occur from rat or human TRPV1 to 
oTRPV1, and this could modify its sensitivity to vanilloids. 
Anyway, even if Tyr511 is a conserved residue across species, 
probably it is not the only responsible for the differences in 
vanilloid sensitivity observed among oTRPV1 and other 
TRPV1s. Investigating the pharmacological differences 
among species, Gavva et al. [14] assessed that oTRPV1 can 
gain functional vanilloid sensitivity with a single residue 
substitution (I550T) and with one additional residue change 
(L547M), gaining also high affinity to (3H)RTX. The same 
study highlighted that the reverse mutation cause the loss of 
vanilloid sensitivity and/or RTX binding for rat and human 
TRPV1[14].  
Cat 
TRPV1 was also identified in feline tissues, and 
considering the similarities with hTRPV1, this species was 
often used as animal model to study several human 
pathologies.   
In 2005, Sculptoreanu and co-workers [31], investigated the 
role of TRPV1 receptor in interstitial cystitis (IC), a 
pathology that can affect feline and human urinary bladder. 
The investigator of this study used patch clamp techniques to 
examine primary afferent neurons during feline interstitial 
cystitis (FIC) and measuring TRPV1 responses to capsaicin 
in DRG neurons in normal and FIC affected cats. FIC 
neurons were increased in size and demonstrated a stronger 
capsaicin response that decreased slowly. Moreover, they 
demonstrated that phorbol 12,13-dibutyrate (PDBu), (a PKC 
activator) could reduce the desensitization of capsaicin 
responses in normal cat bladder and non-bladder neurons, but 
had no effect in FIC neurons. On the other hand, 
bisindolylmaleimide (PKC inhibitor), reversed the PDBu 
effects in normal cat neurons and normalized the 
desensitization of capsaicin responses in FIC neurons. 
Finally, they observed that that abnormalities in afferent 
neuron excitability may occur in DRG neurons innervating 
structures outside the pelvic cavity and this may explain the 
huge variety of  symptoms of interstitial cystitis extend 
beyond the bladder, affecting other organs in the body.  
The research group of Keay in 2014 [32], studied the role of 
urothelium in regulating bladder function during pathological 
conditions such as bladder pain syndrome/interstitial cystitis 
(BPS/IC), FIC and non-neurogenic idiopathic overactive 
bladder (OAB). All the mentioned pathologies are 
characterized by symptoms concerning lower urinary tract, 
such as urgency, incontinence, nocturia, and pain. Keay and 
co-workers[32]compared symptomatic and asymptomatic 
humans and cats, discovering that all symptomatic patients 
share some common features, including increased purinergic, 
TRPV1, and muscarinic signalling, increased urothelial 
permeability, and aberrant urothelial differentiation.  
The study of Cheng et al.[33], identified the presence of 
TRPV1 in oesophageal mucosa in cats. Moreover, this study 
demonstrated the activation of TRPV1 by HCl and its 
enrolment in acid-induced inflammation and contraction of 
this organ. Capsaicin inhibits the contractions while 5-I-RTX 
had the opposite effect [33]. The results showed that TRPV1 
HCl-induced activation in oesophageal mucosa induce the 
release of substance P and CGRP release from neurons and 
PAF release from epithelial cells [33]. 
A recent study [34] tried to demonstrate the role of TRPV1 
in feline asthma. For this experiment, five cats were treated 
using Bermuda grass allergen (BGA) in order to induce 
asthma and 24 hours after this first sensitization, cats were 
treated with capsaicin. Unexpectedly and in contrast to the 
experimental hypothesis and to previously published data 
concerning asthma in other species, capsaicin did not result 
in concentration-dependent increases in airway resistance in 
a feline asthma model.  
Dog  
The first time that TRPV1 was identified in canine tissues 
was during the study of Phelps et al. [15]. Their project was 
addressed to clone dog TRPV1 cDNA from dog nodose 
ganglia, and to characterize this orthologue in transfected 
HEK293OFF cells. The dog orthologue showed the same 
structure and a strong homology to other mammalian TRPVs 
(89.3% to rabbit, 89.1% to human, 87.5% to rat, 85.2% to 
guinea pig, and 83.3% to mouse).  
As explained previously, mammalian TRPV1 can be 
subdivided upon their functional response to capsaicin, based 
on the single threonine residue at amino acid position 550 in 
TM3 and TM4 regions. Dog TRPV1 contains a threonine 
residue at position 550, suggesting a possible activation of the 
receptor by capsaicin. The primary amino acid sequence of 
dTRPV1 revealed the presence of a methionine at position 
547: the same site is responsible for PPAHV binding in 
rTRPV1[35, 36], and actually also dTRPV1 is responsive to 
PPAHV [15]. Phelps et al. [15] highlighted that the Hill slope 
value corresponding to resiniferatoxin was less than one, 
suggesting a negative cooperation of the dog receptor for this 
agonist. Moreover, dTRPV1 lacks serine at position, which is 
responsible for the sensitization of TRPV1 to PKA 
phosphorylation and to capsaicin: consequently, in dTRPV1, 
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these kind of activations might increase nociceptive 
perception [15]. The behaviour of dTRPV1 resulted the same 
of hTRPV1 and gpTRPV1 and opposite to rTRPV1 when 
exposed to BCTC and 5-I-RTX. Part of these findings was 
confirmed by Premkumar and Sikand[37]: capsazepine 
inhibits acid-induced activation of hTRPV1, but has no 
effects on the same activation in rTRPV1, but at the same 
time is able to inhibit heat-induced TRPV1 activation both in 
humans and rat. 
The pharmacological features of dTRPV1 similar to 
human’s orthologue, suggest that dog could be considered a 
good model for studying the role of TRPV1 in inflammatory 
diseases and nociception. 
In 2013, TRPV1 expression in canine mammary 
adenocarcinoma cells, CF.41, was demonstrated [38]. In this 
study, the expression and functionality of dTRPV1 was 
investigated in a tumour cell line in comparison to human 
breast adenocarcinoma cell line (MCF-7 cells), where 
TRPV1 was first identified by Barbero et al. in 2006 [39]. 
Experiments on cell proliferation were done using 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) technique and the results highlighted that all 
tested ligands (both agonists and antagonists) caused a 
significant decrease in MCF-7 cell proliferation. On the 
contrary, capsaicin and capsazepine were able to reduce 
significantly CF.41 cell proliferation. As cited previously, 
these results could depend on species-specific TRPV1 
differences: capsaicin could activate rTRPV1 thanks to its 
binding with Arg114 and Glu761 residues [40]. To explain the 
different results obtained by vanilloid ligands on MCF-7 and 
CF.41 proliferation, it is possible that capsaicin and 
capsazepine might interact with TRP or non-TRP receptors. 
Hwanget al. [41] demonstrated that capsaicin act sinergically 
with 12-O-tetradecanoylphorbol-13-acetate (TPA) and can 
cause skin carcinogenesis, stimulating epidermal growth 
factor receptor. The cited study, used MTT proliferation 
assay that unfortunately is not useful to obtain information 
concerning the TRPV1 molecular mechanism underlying 
these responses, but the results seem to suggest that 
TRPV1-mediated effects in a canine model are not a good in 
vitro model for human breast adenocarcinoma. 
Swine 
Swine TRPV1 was recently investigated in the study of 
Hayes et al. [42] concerning the role of vagal nerve in the 
pulmonary neurobiology of acute lung injury. Authors 
explained that although differences exist between swine and 
human anatomy, the patterns of the vagal nerve are largely 
similar and closer in size than standard rodent models and for 
these reasons they tried to use swine as animal model to 
investigate human acute lung injury. In this study it was 
possible to demonstrate the presence of TRPV1 using 
immunofluorescence staining in nodose. Anyway, authors 
carefully aware that some species-specific changing can 
occur and that further studies are required.  
Capsazepine: a (not always) TRPV1 antagonist. 
One interesting finding of the study of Correllet al. [13] is 
that BCTC and 5-I-RTX function as potent antagonists 
across species against capsaicin, low pH-induced, and PKC 
mediated response. It was demonstrated that capsazepine 
cannot antagonize either acidic pH or PMA-induced 
mTRPV1 activation but can contrast a capsaicin-induced 
response. Differently, capsazepine completely blocks both a 
PMA-induced activation of hTRPV1 [20; 43], and a 
pH-induced activation of hTRPV1 [44] or gpTRPV1 [12]. 
mTRPV1 is pharmacologically more similar to rTRPV1, 
rather than hTRPV1 or gpTRPV1. Considering what 
previously mentioned, capsazepine can inhibit 
capsaicin-induced activation of TRPV1 but cannot block a 
pH-induced or PKC-mediated activation of TRPV1 in 
rodents, making this receptor different from other TRPV1 
orthologues.  
Moreover, capsazepine cannot reverse either 
carageenan-induced thermal hyperalgesia or in mechanical 
hyperalgesia in rat and mouse TRPV1, but can in guinea pigs 
[45]. The data of Correll et al. [13] are consistent with this 
argument and confirm that capsazepine is only able to inhibit 
a capsaicin-induced response for mTRPV1.  
The activation of TRPV1 mediated by PKC should be 
inhibited to obtain an efficient antagonism of TRPV1 
function in vivo, particularly under inflammatory conditions 
where activation of membrane receptors such as TrkA, 
P2Y1, or BK2 would lead to PKC-induced activation of 
TRPV1. The study of Gavva and colleagues [14] examining 
the importance of various conserved residues and identified 
the residue Leu547, which appears to be essential for 
capsazepine antagonism after proton activation. Leucine is 
present in this position for human, guinea pig and rabbit 
TRPV1, while a methionine is present in that position for rat 
and for mouse TRPV1.  
In rTRPV1, the residues I514M, V518L, and M547L allowed 
capsazepine to inhibit a pH-induced response for rTRPV1:  
functional assays confirm that these residues are involved in 
capsazepine interaction with different TRPV1 orthologues, 
and consequently can determine antagonist efficacy, 
particularly in regards to the various modalities of activation 
[36].  
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TRPV1 in comparative medicine 
As mentioned at the beginning, during the last decades, 
several animal species were used as animal model for humans 
to investigate for possible therapeutic use of TRPV1, with a 
special attention to neuropatic and inflammatory pain and to 
oncology.  
The paper of Trevisani et al. [46] deals with the ability of 
5-I-RTX to inhibit cough induced by inhalation of capsaicin 
and citric acid in non- anaesthetized guinea pigs. 5-I-RTX is 
known to be an ultra-potent TRPV1 antagonist and in this 
study it was administered intraperitoneally or by aerosol 
before the stimulation with agonists. 5-I-RTX was able to 
reduce cough stimulation in a dose dependent manner. They 
proposed the therapeutic use of 5-I-RTX as antitussive drug. 
In must be underlie, that systemic administration of TRPV1 
antagonists should be carefully considered because it could 
lead to the change of body temperature, gastrointestinal and 
cardiovascular functions. Furthermore, the blockade of 
TRPV1 has been shown to increase its own expression, 
thereby raising the possibility of rebound effects [37]. 
TRPV1 is expressed in C-fibre bladder afferents and also 
in urothelial cells from both rats [47] and humans [48]. 
Different investigators have studied the role of TRPV1 in 
OAB by using human urothelial tissues [32]. This pathology 
was separated into “sensory urgency” versus “detrusor 
overactivity” and in both situations it was observed an 
increasing TRPV1 mRNA expression, associated with 
sensory urgency, but not detrusor overactivity[49]. A study of 
Rios et al. [50] observed that treatment with resiniferatoxin 
(RTX), which blocks TRPV1, in not effective in patients 
with idiopathic detrusor overactivity and urgency 
incontinence (considered as idiopathic OAB). The trial of 
Apostolidis et al. [51] found a positive effect in patients with 
neurogenic OAB using a dose of 50nM of RTX. Taking into 
consideration these results, Keay et al. [32]concluded that the 
positive effects of RTX in OAB treatment are stronger in 
neurogenic patients (for instance, OAB post spinal cord 
injury) rather than in idiopathic OAB. Unfortunately all the 
mentioned studies could not complete clarify the role of 
TRPV1 in OAB because even if animal models are valuable 
tools to test perturbations in urothelial function, they not 
complete reflect the human pathology.  
Some studies tried to understand if the level of expression 
of TRPV1 could be used as diagnostic or prognostic marker: 
some results highlighted that increased levels of TRPV1 are 
associated with a better prognosis of patients with 
hepatocellular carcinoma, whereas expression of TRPV1 is 
decreased in the urothelium of patients with advanced stage 
transitional cell carcinoma, [52]. In human breast cancer cells 
lines such as MCF-7, the overexpression of TRPV1 
compared to normal gland can be considered a suitable 
prognostic marker [53]. Other studies showed that the 
receptor-mediated anti-tumour activity should be associated 
with induction of apoptosis following activation of TRPV1 
and changes in cell calcium influx: calcium is involved in 
physiological cell processes and abnormal calcium 
functioning may occur during cancerogenesis[54]. Therefore, 
calcium channels could serve as anti-cancer therapeutic 
targets, because besides pro-apoptotic action, the activation 
of TRPV1 leads to anti-angiogenic, anti-migrative, 
anti-adhesive and anti-metastatic effects[55].  
Oncologic researches demonstrated that TRPV1 is 
implicated not only in cell proliferation but also in pain 
modulation correlated to cancer, and several studies 
described the binding characteristics and clinical efficacy of 
selective TRPV1 agonists and antagonists [56]. TRPV1 
mutations can lead to changes in TRPV1 responses to agonist 
stimulation: mutations at the sixth TRPV1 transmembrane 
domain can cause, for example, the reduction 
of 3(H)RTX-binding affinity and mutations on pore domain 
significantly decrease the sensitivity to capsaicin [57]. The 
results of Vercelli et al. [38] of proliferation assays performed 
on MCF-7 cells confirmed the potential of TRPV1 agonists 
as anti-cancer drugs. These results found a confirmation in 
other studies that demonstrated that capsaicin could inhibit 
human cancer hormone-resistant cells and can provide 
chemopreventive effects [58]. Moreover, other studies 
demonstrated that capsaicin can mediate cell death of T24 
(human bladder cancer), A172 (human glioma) [59; 60], and 
MCF-7 [61] cell lines, nevertheless the use of TRPV1 ligands 
in cancer treatment should always be careful, as explained 
previously.  
Conclusions 
The interest of the scientific community in TRPV1 
increased significantly since this receptor has been identified 
in 1997. Looking at all the data available in literature, it 
seems clear that TRPV1 has a key role in modulation of 
inflammatory events, transmission and perception of pain, 
and recently it was demonstrated is enrolment in cancer 
aetiology and evolution. This interest was first address to 
human beings but nowadays it turns to Veterinary Medicine, 
looking for new therapeutic strategies. At the same time, 
discoveries concerning TRPV1 could be cross related in 
human or in veterinary medicine, always taking into 
consideration similarities and differences among species.  
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